Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 13/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201123 | 0.86 | HPGD (0.50) | MEN1KMT2AHPGDRAB9ALMNA | |
| SCHEMBL8490672 | 0.84 | HPGD (0.64) | MEN1KMT2APARP1PARP10PARP15 | |
| SCHEMBL555511 | 0.84 | HPGD (0.48) | MEN1KMT2AHPGDRAB9ALMNA | |
| SCHEMBL555091 | 0.84 | HPGD (0.48) | MEN1KMT2AHPGDRAB9ALMNA | |
| SCHEMBL1127078 | 0.83 | RAB9A (0.67) | MEN1KMT2AHPGDRAB9ALMNA | |
| SCHEMBL20169847 | 0.81 | SMN1; SMN2 (0.65) | MEN1KMT2APARP1PARP10PARP15 | |
| SCHEMBL11782094 | 0.81 | KMT2A (0.49) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL10192014 | 0.80 | HSD17B10 (0.53) | MEN1KMT2AHPGDRAB9ALMNA | |
| SCHEMBL832082 | 0.80 | RAB9A (0.64) | MEN1KMT2APARP1PARP10PARP15 | |
| SCHEMBL29687812 | 0.80 | RAB9A (0.64) | MEN1KMT2APARP1PARP10PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3888632-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3412279-B1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE GENERAL HOSPITAL CORPORATION | 2021-01-14 | — | — | US | disclosed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012040623-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | MMP2, CEL, LIPA | MEN1 3515/4885KMT2A 3895/4885PARP1 2727/4885 |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | MEN1 3515/4885KMT2A 3895/4885PARP1 2727/4885 |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | MEN1 3515/4885KMT2A 3895/4885PARP1 2727/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | MEN1 3859/4885KMT2A 4034/4885PARP1 2651/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | MEN1 3515/4885KMT2A 3895/4885PARP1 2727/4885 |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | MEN1 3515/4885KMT2A 3895/4885PARP1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.